other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies
The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes across five global registrational trials
They have knee pain, tendon pain, back pain, prior surgeries, poor conditioning, or exercise intolerance
GLP-1 medications and related incretin therapies can make food feel different: appetite drops, fullness arrives earlier, rich foods may sit heavily, and old meal-prep habits may stop working
the evidence is limited to animal models and the finding should not be extrapolated beyond that context
Think of it as giving the gas pedal an extra push while also making the engine more responsive